Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) insider Mitchell Lawrence Jones sold 51,880 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total transaction of $106,354.00. Following the completion of the sale, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. This trade represents a 35.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Palisade Bio Price Performance
PALI stock traded down $0.03 during mid-day trading on Wednesday, reaching $2.05. The company had a trading volume of 3,270,900 shares, compared to its average volume of 4,120,142. The company has a market capitalization of $355.84 million, a PE ratio of -2.03 and a beta of 1.50. The firm has a 50 day moving average of $1.91 and a 200 day moving average of $1.92. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.86.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts anticipate that Palisade Bio, Inc. will post -0.25 EPS for the current year.
Hedge Funds Weigh In On Palisade Bio
Wall Street Analyst Weigh In
Several research analysts have commented on PALI shares. HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Wolfe Research began coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $8.83.
Check Out Our Latest Research Report on PALI
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Featured Articles
- Five stocks we like better than Palisade Bio
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
